Physician profile
Rafael Medrano
NPI 1043210792
$8,125.28
in general payments reported to CMS, 2019-2025
34 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $763 · 2021: $1,363 · 2022: $1,188 · 2023: $1,415 · 2024: $975 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,491 · Debt Forgiveness: $74.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,491.25 |
| Debt Forgiveness | $74.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,169.28 | 2019-2025 | Cardiomems, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $900.09 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $617.43 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $490.73 | 2022-2025 | General - Tachy, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $437.81 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $421.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $339.88 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.24 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $302.17 | 2021-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $270.27 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $255.53 | 2022-2025 | Lifevest |
| Allergan, INC. | $229.44 | 2019-2020 | |
| Abiomed | $178.95 | 2021-2025 | |
| Medtronic, INC. | $139.70 | 2023 | Corevalve Evolut R |
| Bardy Diagnostics, INC. | $125.00 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $124.31 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $93.19 | 2023-2024 | (5091) Amb Mon & Diag Und |
| Medicomp INC | $90.41 | 2024 | Telepatch Cardiac Monitor |
| Abbvie INC. | $87.82 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $78.80 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $64.63 | 2024-2025 | Wegovy, Ozempic |
| Alnylam Pharmaceuticals INC. | $60.35 | 2019-2023 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $43.01 | 2019-2024 | Evkeeza |
| Amarin Pharma, INC. | $41.32 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $40.58 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $34.70 | 2022-2023 | Arcalyst |
| Vivaquant INC, Dba Rhythm Express | $32.93 | 2024 | Rhythm Express |
| Scpharmaceuticals INC. | $30.98 | 2023-2024 | |
| Inspire Medical Systems, INC. | $25.15 | 2023 | Inspire |
| Chiesi USA, INC. | $24.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.02 | 2025 | |
| Genzyme Corporation | $17.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.96 | 2019 | |
| Tactile Systems Technology INC | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Medrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.